Guided Therapeutics Inc. (OTCMKTS:GTHP) Sees Large Drop in Short Interest

Guided Therapeutics Inc. (OTCMKTS:GTHP) was the target of a large decline in short interest in the month of December. As of December 15th, there was short interest totaling 1,846 shares, a decline of 28.4% from the November 30th total of 2,580 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily trading volume, of 13,148 shares, the short-interest ratio is presently 0.1 days. Based on an average daily trading volume, of 13,148 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Guided Therapeutics Price Performance

Guided Therapeutics stock traded up $0.01 during trading hours on Monday, hitting $0.37. The company had a trading volume of 6,444 shares, compared to its average volume of 13,568. The firm has a 50-day moving average of $0.26 and a 200 day moving average of $0.25. The firm has a market cap of $32.19 million, a PE ratio of -7.49 and a beta of 0.64. Guided Therapeutics has a one year low of $0.06 and a one year high of $0.47.

Guided Therapeutics (OTCMKTS:GTHP) last posted its earnings results on Thursday, November 13th. The company reported ($0.01) earnings per share for the quarter. The firm had revenue of $0.06 million during the quarter.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non?invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.

The company secured 510(k) clearance from the U.S.